Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: Significance in clinicopathological outcomes following radical prostatectomy

BJU International

Volumn 111, Issue 1, 2013, Pages 30-37

  Behnsawy, Hosny M ^a,b   Miyake, Hideaki ^a   Harada, Ken Ichi ^a   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Assiut University Faculty of Medicine   (Egypt)

Author keywords

biochemical recurrence; epithelial mesenchymal transition; prostate cancer; radical prostatectomy

Indexed keywords

BETA CATENIN; FIBRONECTIN; GELATINASE A; GELATINASE B; NERVE CELL ADHESION MOLECULE; PLAKOGLOBIN; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL PREDICTION; SURVIVAL RATE;

EID: 84871617813     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11551.x     Document Type: Article

References (29)

1. Amling CL., Biochemical recurrence after localized treatment. Urol Clin North Am 2006; 33: 147-159
2. Quinn DI, Henshall SM, Haynes AM, et al. Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol 2001; 19: 3692-3705
3. Karakiewicz PI, Eastham JA, Graefen M, et al. Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology 2005; 66: 1245-1250
4. Kattan MW, Easthan JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 766-771
5. D'Amico AV, Whittington R, Kaplan I, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974
6. Mackinnon AC, Yan BC, Joseph LJ, Al-Ahmadie HA., Molecular biology underlying the clinical heterogeneity of prostate cancer: an update. Arch Pathol Lab Med 2009; 133: 1033-1040
7. Thiery JP, Acloque H, Huang RY, Nieto MA., Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890
8. Roussos ET, Keckesova Z, Haley JD, Epstein DM, Weinberg RA, Condeelis JS,. AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment. Cancer Res 2010; 70: 7360-7364
9. Xu J, Wang R, Xie ZH, et al. Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate 2006; 66: 1664-1673
10. Drake JM, Strohbehn G, Bair TB, Moreland JG, Henry MD,. ZEB1 enhances transendothelial migration and represses the epithelial phenotype of prostate cancer cells. Mol Biol Cell 2009; 20: 2207-2217
11. Zhu ML, Kyprianou N,. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J 2010; 24: 769-777
12. Graham TR, Zhau HE, Odero-Marah VA, et al. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2008; 68: 2479-2488
13. Voulgari A, Pintzas A,. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 2009; 1796: 75-90
14. Zhang Q, Helfand BT, Jang TL, et al. Nuclear factor-κB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res 2009; 15: 3557-3567
15. Contreras HR, Ledezma RA, Vergara J, et al. The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and β-catenin, in prostate cancer. Urol Oncol 2010; 28: 534-540
16. Walsh PC., Radical prostatectomy: a procedure in evolution. Semin Oncol 1994; 21: 662-671
17. Koch MO., Management of the dorsal vein complex during radical retropubic prostatectomy. Semin Urol Oncol 2000; 18: 33-37
18. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL,. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228-1242
19. Sakai I, Harada K, Hara I, Eto H, Miyake H,. A comparison of the biological features between prostate cancers arising in the transition and peripheral zones. BJU Int 2005; 96: 528-532
20. Kurahashi T, Miyake H, Hara I, Fujisawa M,. Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. J Urol 2007; 177: 757-761
21. Conant JL, Peng Z, Evans MF, Naud S, Cooper K,. Sarcomatoid renal cell carcinoma is an example of epithelial-mesenchymal transition. J Clin Pathol 2011; 64: 1088-1092
22. Harada K, Miyake H, Kusuda Y, Fujisawa M,. Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy. BJU Int 2012 [Epub ahead of print] DOI: 10.1111/j.1464-410X.2012.11297.x
23. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006; 98: 715-717
24. Zellweger T, Ninck C, Bloch M, et al. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005; 113: 619-628
25. Inoue T, Segawa T, Shiraishi T, et al. Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 2005; 66: 332-337
26. Lee TK, Poon RT, Yuen AP, et al. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 2006; 12: 5369-5376
27. Takechi H, Ito K, Yamamoto T, Miyakubo M, Ohi M, Suzuki K,. Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan. Urology 2008; 72: 1111-1115
28. Li Y, VandenBoom TG 2nd, Kong D, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009; 69: 6704-6712
29. Kong D, Banerjee S, Ahmad A, et al. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. Plos ONE 2010; 5: e12445